Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2021-08-20 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于贝达药业股份有限公司对外投资暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent verification opinion from CITIC Securities regarding an external investment and related party transaction by Betta Pharmaceuticals Co., Ltd. It includes comprehensive information about the investment, the related parties, financial data, transaction pricing, agreements, approvals, and risk disclosures. The content focuses on the due diligence and compliance aspects of a specific investment transaction rather than presenting a full financial report, earnings release, or management discussion. It is not a general regulatory filing or a brief announcement but a formal audit or verification opinion related to a specific transaction. Therefore, it fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to specific transactions or stress tests, excluding full annual reports. H1 2021
2021-08-20 Chinese
2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "贝达药业股份有限公司 2021 年半年度报告全文" which translates to "Betta Pharmaceuticals Co., Ltd. 2021 Semi-Annual Report Full Text." It contains detailed sections including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, important matters, shareholder information, preferred stock, bonds, and financial statements. The report covers the period from January 1, 2021 to June 30, 2021, indicating it is a comprehensive interim financial report. The length is about 15,000 characters, which is substantial and contains actual financial data and analysis, not just an announcement or summary. The content includes management discussion and analysis, financial metrics, business overview, and operational review, consistent with an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-09 Chinese
独立董事关于第三届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent directors' opinion on matters related to the 21st meeting of the third board of directors and the company's 2021 semi-annual report period. It discusses compliance with regulations on external guarantees, fund usage, and related party transactions during the 2021 half-year period. The document is a formal opinion letter from independent directors rather than the actual semi-annual report or financial statements. It does not contain substantive financial data or detailed financial analysis itself but rather an independent opinion on specific governance and compliance matters related to the half-year report. The document length is short (1966 characters), and it is a formal opinion letter, not a full report or announcement of a report publication. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on governance and compliance issues.
2021-08-09 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021 半年度报告摘要' which translates to '2021 Half-Year Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period. It also discusses business operations, R&D progress, and shareholder information. The presence of comprehensive financial metrics and operational commentary indicates this is a substantive interim financial report rather than a brief announcement or summary. The document length is about 4794 characters, which is sufficient for a half-year report summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-09 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 21st meeting of the 3rd Board of Directors of Betta Pharmaceuticals Co., Ltd. It includes details about the meeting's convening, attendance, and voting results on specific agenda items such as the approval of the 2021 semi-annual report and a special report on the use of raised funds. The document explicitly states that the full semi-annual report and related disclosures are published elsewhere and provides links to those announcements. The document itself does not contain the full financial report or detailed financial data but rather the board's approval and summary of decisions. This fits the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters. The document length is short (1076 characters), and it is not the report itself but an announcement of board resolutions related to reports. Therefore, the correct classification is MANG with high confidence.
2021-08-09 Chinese
2021年半年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金存放与使用情况专项报告" which translates to a "Special Report on the Deposit and Use of Raised Funds" for the half-year period of 2021. It details the amounts of funds raised through stock issuance, their storage, usage, investment projects, changes in investment projects, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed financial tables on the use and balance of raised funds. It is a specialized report focusing on the management and use of capital raised by the company, not a general financial report or earnings release. This type of report fits best under the category of Capital/Financing Update (CAP), as it provides updates on the company's fundraising and the use of those funds. The document length is substantial and contains detailed financial data related to capital usage, supporting this classification with high confidence.
2021-08-09 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.